Dysregulation of CDK inhibitors and p53 in HPV-negative endocervical adenocarcinoma.
By: Makiko Omori, Akihiko Hashi, Tetsuo Kondo, Ryohei Katoh, Shuji Hirata

Department of Obstetrics and Gynecology (M.O., A.H., S.H.) Department of Pathology (T.K., R.K.), Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
2015-2-13; doi: 10.1097/PGP.0000000000000121
Abstract

Human papillomavirus (HPV)-negative adenocarcinoma (AC) is a minor subset of endocervical cancer, but its pathogenesis has yet to be elucidated. This study investigated the clinicopathologic features of HPV-negative endocervical AC (n=14) in comparison with HPV-positive endocervical AC (n=30), and further studied aberrations of cell-cycle regulators. Expression patterns of cyclin-dependent kinase inhibitors (p16, p14, p27, and p21) and p53 were evaluated immunohistochemically, and nuclear high-risk HPV DNA signals were detected by in situ hybridization and polymerase chain reaction. Immunoexpression of p16, p14, p27, p21, and p53 were observed in 90%, 67%, 77%, 40%, and 20% of HPV-positive ACs, and in 0%, 0%, 29%, 14%, and 57% of HPV-negative ACs, respectively. A higher frequency of lymph node metastasis and worse prognosis were significantly associated with HPV-negative AC. Our findings suggest that alteration of cyclin-dependent kinase inhibitors and p53 status may contribute to carcinogenesis and the clinical behavior of HPV-negative AC of the uterine cervix.





PMID:25675191






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements